Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS).
Long-term retention after structured curriculum on attainment of critical view of safety during laparoscopic cholecystectomy for surgeons.
Similar magnitude of post-exercise hyperglycemia despite manipulating resistance exercise intensity in type 1 diabetes individuals.
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
See All 6 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
View in:
PubMed
subject areas
Antiemetics
Antineoplastic Agents
Half-Life
Humans
Nausea
Neoplasms
Neurokinin-1 Receptor Antagonists
Randomized Controlled Trials as Topic
Spiro Compounds
Vomiting
authors with profiles
Rudolph Navari